3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
4
Recurrence
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
Lenalidomide
11
Dexamethasone
11
fludarabine
9
Cyclophosphamide
7
Bortezomib
6
fludarabine phosphate
5
Melphalan
5
pomalidomide
4
isatuximab
3
daratumumab
3
Tacrolimus
3
Mycophenolic Acid
3
Busulfan
3
dacetuzumab
2
Whole-Body Irradiation
2
Thiotepa
2
Stem Cell Transplantation
2
Leukapheresis
2
KW-2478
2
Granulocyte Colony-Stimulating Factor
2
Cyclosporine
2
Calcium Dobesilate
2
tanespimycin
1
spartalizumab
1
sargramostim
1
ricolinostat
1
pirtobrutinib
1
pembrolizumab
1
nirogacestat
1
ixazomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
tanespimycin
×
Plasma cell
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled